Searchable abstracts of presentations at key conferences in endocrinology

ea0021oc5.6 | Steroids and thyroid | SFEBES2009

Is it safe for patients taking thyroxine to have a low but not suppressed serum TSH concentration?

Leese Graham , Flynn Robert

For patients taking thyroxine replacement guidelines generally recommend aiming for a target TSH within the laboratory reference range. The evidence for this guidance is generally based on an extrapolation of data from patients with endogenous subclinical thyroid disease. We aimed to examine the safety of having a TSH which was either suppressed (≤0.03 mU/l), low (0.04–0.4 mU/l), ‘normal’ (0.4–4.0 mU/l) or raised (>4.0 mU/l) in a population-based ...

ea0015oc38 | Thyroid | SFEBES2008

Serious vascular events for patients on long-term thyroxine: the TEARS Study

Leese Graham , Jung Roland , Flynn Robert

The TEARS database links six datasets for patients with treated and stabilised thyroid conditions. It has been validated previously and represents a population-based patient sample, as patient identification includes using regional-wide biochemical records and prescription data. For patients on long-term thyroxine we examined the outcome of ‘serious vascular events’ defined as vascular death, non-fatal myocardial infarction and non-fatal stroke as used in the Anti -t...

ea0013p338 | Thyroid | SFEBES2007

The relative level and predictors of osteoporotic fracture in patients with treated thyroid dysfunction

Flynn Robert , Bonellie Sandra , Jung Roland , Morris Andrew , Macdonald Thomas , Leese Graham

Objectives: (1) to establish the relative level of osteoporotic fracture in the thyroid population compared to the general population, and (2) to establish whether osteoporotic fracture in patients receiving thyroxine was associated with plasma thyroid stimulating hormone (TSH) level or thyroxine dose.Method: A database of clinical information from subjects with treated thyroid disease was linked to morbidity records describing all in-patient episodes of...